Advertisement
Organisation › Details
Debiopharm (Group)
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of five companies active in the development and manufacture of drugs and diagnostics tools. Debiopharm focuses on developing prescription drugs that target unmet medical needs. The group in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. *
Start | 1979-01-01 established | |
Industry | BIOTECH | |
Person | Mauvernay, Rolland-Yves (Debiopharm 201301 President + Founder) | |
Region | Lausanne VD | |
Country | Switzerland | |
Street | 5–7 Chemin Messidor Forum »après-demain« | |
City | 1002 Lausanne VD | |
Tel | +41-21-321-0111 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Debiopharm (Group)
- [1] Voluntis S.A.. (11/23/20). "Press Release: Voluntis Successfully Completes a Capital Increase of €5.9 Million and Finalizes the Financing of Its Strategic Roadmap [Not for US, CA, AU or JP] Japan.". Cambridge, MA & Paris....
- [2] Debiopharm International SA. (9/7/20). "Press Release: Belgian Scale-up Oncomfort Raises €10 million in Series A Funding Co-led by Debiopharm and Crédit Mutuel Innovation". Brussels, Lausanne & Paris....
- [3] Debiopharm International SA. (7/7/20). "Press Release: Nucleai Secured $6.5m Series-A Initial Closing Led by Debiopharm to Advance Ai-Powered Precision Oncology Platform". Tel Aviv & Lausanne....
- [4] Debiopharm International SA. (3/25/20). "Press Release: Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-licensing Agreement of 3B Pharmaceutical’s Targeted CAIX Radiotherapy". Lausanne....
- [5] Novadiscovery S.A.S.. (1/9/20). "Press Release: Novadiscovery Raises Series A Financing to Scale Its in silico Clinical Trial Platform – Debiopharm Leads the Round with EUR 5 Million"....
- [6] Debiopharm International SA. (6/12/19). "Press Release: Debiopharm and Ipsen Extend Their Strategic Decapeptyl (triptorelin) Partnership for another 15 Years". Lausanne & Paris....
- [7] Debiopharm International SA. (5/14/19). "Press Release: Debiopharm Awarded $2.1 Million from CARB-X in the Fight against a Highly Resistant Nosocomial-pneumonia Causing Superbug". Lausanne....
- [8] Dynacure S.A.S.. (7/10/18). "Press Release: Dynacure Names Chris Freitag (MD) Chief Medical Officer". Strasbourg....
- [9] Debiopharm International SA. (6/20/17). "Press Release: Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor". Craigavon & Lausanne....
- [10] Debiopharm International SA. (5/24/17). "Press Release: Debiopharm International SA Enters the Field of Antibody-Drug Conjugates through Acquisition of Phase II Asset from ImmunoGen". Lausanne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top